PETER GASSER, MD is a Psychiatrist and Psychotherapist in Switzerland.
Recorded at the Interdisciplinary Conference on Psychedelic Research (ICPR) 2022, in Haarlem, The Netherlands.
https://www.icpr-conference.com/
https://drugreporter.net
Questions:
0:00 Intro
0:05 Please introduce yourself and your work!
0:54 What brought you into this field?
1:52 Why are therapists interested in psychedelics?
3:15 How do psychedelics compare to traditional psychiatric drugs?
4:25 Is it the substance that has the healing potential, or is it only the substance embedded in this therapeutic context, assisting psychotherapy?
5:53 What does psychedelic assisted therapy look like in the real world?
7:05 Do you have any exclusion criteria? People you definitely would not work with?
8:18 Can a psychedelic experience induce a psychotic episode in an otherwise healthy individual?
9:24 What kind of training professionals need to provide psychedelic therapy? 
10:34 Do you think therapists need subjective experiences with psychedelic drugs?
11:33 This is a multi hour long session, and must be very exhausting for the therapist. What does it look like from your side?
13:11 Psychedelic therapy now is mostly available for the upper middle class. Do you think the costs can be reduced and made available for the wider public and more marginalised people?
14:24 You did the first human LSD study after the long ban. How do you feel about the current wave of new research?
15:34 How do you see the future of psychedelics will find their way to mainstream medical care?